Is Apexigen, Inc. (APGN) a Buy, Sell, or Hold?
NASDAQ : APGN
Apexigen, Inc.
$0.3851 USD
$0.03 (8.48%)
- Volume
- 94.43K
- Average Volume
- 52.6K
- Market Capitalization
- $9.57M
- P/E Ratio
- -0.24
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $8.28
- Year Low
- $0.33
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.29
Company Overview
NASDAQ
Xiaodong Yang
Biotechnology
Healthcare
APGN
11
US
USD
Liquidity Metrics
0.02
1.29
1.29
0.90
0.00
Sales & Valuation
-$
0.00
1.19
-0.31
-1.55
Profitability
-$1.59
-$31.45M
0.00%
0.00%
48.27%
-137.62%
P/E Metrics
-0.24
0.00
0.00
Analyst Price Target & Rating
0/5
1 Analysts
%
Financial Health Scores
-28.91
3/9
-$2.8M
$13.08M
$15.4M
-$34.94M
Key Metrics (TTM)
-$5.12M
0.00
0.16
1.29
48.27%
-493.64%
-412.75%
-321.17%
0 days
Company Executives
| Name | Title |
|---|---|
| Francis W. Sarena | Pres & Chief Operating Officer |
| Xiaodong Yang | Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Apexigen, Inc. (NASDAQ:APGN) Stock
Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, ... through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.
Frequently Asked Questions
-
What is the current Apexigen, Inc. (APGN) stock price?
-
Apexigen, Inc.(NASDAQ:APGN) stock price is $0.3851 in the last trading session. During the trading session, APGN stock reached the peak price of $8.28 while $0.331 was the lowest point it dropped to. The percentage change in APGN stock occurred in the recent session was 8.48% while the dollar amount for the price change in APGN stock was $0.03.
-
APGN's industry and sector of operation?
-
The NASDAQ listed APGN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of APGN?
-
Francis W. Sarena | Pres & Chief Operating Officer
Xiaodong Yang | Chief Executive Officer & Director
|
|
| -
How many employees does APGN have?
-
Number of APGN employees currently stands at 11. APGN operates from 75 Shoreway Road, San Carlos, CA 94070, US.
-
Link for APGN official website?
-
How do I contact APGN?
-
APGN could be contacted at phone #650-931-6236 and can also be accessed through its website. APGN operates from 75 Shoreway Road, San Carlos, CA 94070, US.
-
How many shares of APGN are traded daily?
-
The average number of APGN shares traded daily for last 3 months was 52.6K.
-
What is the market cap of APGN currently?
-
The market value of APGN currently stands at $9.57M with its latest stock price at $0.3851